The Capital Allocation Dilemma for Fortress ($FBIO / $FBIOP): Pure Math vs. Governance & Reputation. What do you think management does here?

Hey All,

This is a follow up to my earlier post 6 months ago titled "The High-Yield Waiting Game: Why I’m Continuing to Bet on FBIOP Over FBIO Right Now", where I had proposed the arguments on why I considered the preferred FBIOP to be a better investment than the Common FBIO

[https://www.reddit.com/r/investing\_discussion/comments/1qw7i91/the\_highyield\_waiting\_game\_why\_im\_continuing\_to/](https://www.reddit.com/r/investing_discussion/comments/1qw7i91/the_highyield_waiting_game_why_im_continuing_to/)

So far those arguments have been on point as the Preferred - FBIOP has significantly out-performed the Common - FBIO

I’ve been digging into Fortress Biotech’s capital allocation options regarding their Series A Preferred shares ($FBIOP) from where we are now.

The board is facing a major strategic fork, and the two paths benefit very different groups of investors.

I’d love to get the community's perspective on how you think this plays out. Here is a breakdown of the mechanics:

**The Current Math: Two Distinct Paths**

Every share of FBIOP currently represents a claim of roughly **$30.00** ($25.00 liquidation preference + \~$5.00 /share in accrued unpaid dividends across - Approx. 3.43M shares, totaling \~$17M in arrears).

* **Path 1: Resumption at Par Economics**
* Honor the full claim: pay out the $17M arrears and restart the \~$8M/year dividend coupon (or redeem entirely for \~$102M).
* *Outcome:* Preferred holders are made 100% whole; common equity funds it.
* **Path 2: Repurchase at a Discount**
* Buy back shares via open market while the dividend remains paused and the price is depressed.
* When a share is retired, the $25 preference is extinguished, the accrued dividend arrears vanish, and the 9.375% perpetual coupon dies forever.
* *Outcome:* Every dollar spent below the \~$30.00 claim represents a permanent value transfer to common shareholders, yielding an extraordinary return by retiring an expensive fixed-income obligation at a steep discount.

**1. The "Uncomfortable Game Theory" & Market Pricing**

The paused dividend is the exact reason the price has traded at a discount. If the board announces a resumption, the price rallies toward par immediately, destroying the company's buyback discount. Pure common-shareholder math dictates: *repurchase first, resume second.*

However, with the stock recently rebounding near \~$19 on recent PRV sale / pipeline / catalyst news, the easy 2024–2025 discount window ($6–$7) is gone. There’s still a \~33% discount to the full claim, but with low daily volume, an open-market sweep isn't viable - a formal tender offer would be required, which itself signals intent and drives prices higher.

**2. The Governance Overhang (The 2-Director Provision)**

Per the prospectus, because dividends are past six quarters in arrears, FBIOP holders now have the right to expand the board and elect **two independent directors**. For a founder-led company, hostile board seats represent a real activist threat (especially from funds specializing in busted preferreds). Curing the arrears extinguishes this right, making the timing of this decision critical.

**3. Reputational Franchise Risk**

Fortress's entire business model relies on serial capital formation - issuing equity and debt across its network of subsidiaries. Income investors and underwriters have long memories. Aggressively squeezing preferred holders by repurchasing at distress pricing before making them whole could permanently impair their ability to raise cost-effective capital in the future.

**A Likely Middle Ground?**

A plausible compromise could be a formal tender offer at a slight premium to current market prices but still at a discount to the full claim (e.g., low-to-mid $20s). This lets willing holders exit, captures value for the common equity, and is immediately followed by curing the remaining arrears to eliminate the board-seat threat and restore market standing.

**What are your thoughts?**

Do you see the board aggressively prioritizing common equity math, or will governance and market access force a clean cure?

Personally, I hope management decides to do the right thing by their long-term investors - honoring their commitments and restoring trust - rather than taking full advantage of the paused dividend to squeeze preferred holders for short-term common equity gains.